Cardiovascular Diseases Clinical Trial
Official title:
Improving Coronary Prevention in a County Health System
Verified date | February 2014 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.
Status | Completed |
Enrollment | 419 |
Est. completion date | March 2008 |
Est. primary completion date | March 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 35 Years to 85 Years |
Eligibility |
Abbreviations: FBS = fasting blood sugar, SBP = systolic blood pressure, DBP = diastolic
blood pressure, LDL = low-density lipoprotein, HDL = high-density lipoprotein, BMI = body
mass index, TC = total cholesterol, TG = triglycerides, HbA1c = hemoglobin A1c. Inclusion Criteria - The patient has CAD or CAD risk equivalent (abdominal aortic aneurysm, peripheral vascular disease, transient ischemic attack, stroke, diabetes, or FBS = 126 mg/dL × 2) and has at least one of following: SBP = 130 mmHg, DBP = 80 mmHg, LDL = 100 mg/dL, HDL = 40 mg/dL, TG = 150 mg/dL, FBS = 126 mg/dL, BMI = 30, or is a current smoker. - The patient does not have CAD or CAD risk equivalent but has at least one of the following: SBP = 160 mmHg, DBP = 100 mmHg, LDL = 190 mg/dL, TC = 240 mg/dL, TG = 500 mg/dL, HbA1c = 8.0%, BMI = 35, or is a current smoker. - The patient does not have CAD or CAD risk equivalent but has at least two of the following: a) SBP = 140 mmHg or DBP = 90 mmHg, b) HDL = 40 mm/dL or TG = 200 mg/dL, c) LDL = 160 mg/dL or TC = 240 mg/dL, d) FBS = 110 mg/dL × 2, or e) male age = 45 or female age = 55 or with positive family history of CAD. Exclusion Criteria: - Resident of long-term facility - Lack of spoken English or Spanish by patient or household member 18 years or older who can serve as an interpreter - Moving before end of intervention (30 months) - Age between 35 and 85 (inclusive) - Significant comorbidities such as: uncontrolled metabolic disorders (renal failure, liver failure, etc.), active symptoms suggesting acute myocardial infarction or decompensated congestive heart failure, Malignancy or other condition limiting life expectancy, psychiatric disorder with active manifestations. - Substance abuse. - No telephone or means of contacting patient. - Family household member already enrolled. - Homeless and not living with relatives/friends. - Anticipated absence for more than 4 consecutive months. - Difficulty coming to appointments approximately every 1-2 months - Already participating in the Diabetes program - Currently pregnant or intends to get pregnant the next 3 years. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Stanford University | National Heart, Lung, and Blood Institute (NHLBI) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Framingham Risk Score | Global Cardiovascular disease (CVD) risk score, according to the 1998 sex-specific Framingham point score algorithms of Wilson et al | 15 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|